1. Description — Clinical summary
Parabolan (active compound: trenbolone hexahydrobenzylcarbonate, commonly abbreviated “trenbolone”) is a potent androgenic–anabolic steroid (AAS) delivered by intramuscular injection as an oil-based depot ester. It was originally developed for veterinary/cattle use and at times has been produced in ester form intended for long-acting intramuscular administration. Trenbolone is not an approved, routinely prescribed medication for most human medical indications in many jurisdictions. Human use is largely off‑label and investigational and is associated with significant risk.
Key practical points
- Active ingredient: trenbolone (ester form: hexahydrobenzylcarbonate in the named product). The ester determines the duration of release after IM injection.
- Formulation: oil-based injectable solution (e.g., labeled 100 mg/mL in the product you referenced).
- Regulatory status: not approved for general human therapeutic use in many countries; primarily a veterinary/anabolic compound. Use in humans should only occur under explicit medical oversight (e.g., an approved clinical trial).
2. How does parabolan work? — Mechanism of action
- Androgen receptor agonism: Trenbolone binds the androgen receptor with high affinity and activates androgen-dependent transcription. It is far more potent than testosterone for both anabolic and androgenic effects.
- Anabolic effects: promotes protein synthesis, nitrogen retention, and increases IGF-1 activity in muscle tissue — leading to increased muscle mass and strength in some settings.
- Non-aromatizing but progestogenic: trenbolone does not aromatize to estradiol (so classical estrogenic side effects from aromatization are typically absent). However, trenbolone exhibits progestogenic activity at the progesterone receptor; this can produce estrogen-like downstream effects (e.g., predisposition to gynecomastia in some users) despite lack of aromatization.
- Endocrine suppression: exogenous trenbolone suppresses the hypothalamic–pituitary–gonadal (HPG) axis, leading to reduced luteinizing hormone (LH), follicle-stimulating hormone (FSH) and endogenous testosterone production; prolonged use can cause hypogonadism and infertility.
- Hematologic and metabolic effects: increases erythropoiesis (raises hematocrit/hemoglobin), negatively affects lipid profile (reduces HDL, raises LDL), and can alter glucose metabolism and insulin sensitivity.
- Cardiovascular and renal effects: through changes in lipids, blood pressure, and hematocrit, trenbolone use increases cardiovascular risk. Some reports associate trenbolone with renal function changes, but primary renal toxicity is not well characterized.
Pharmacokinetics (general)
- Depot IM administration results in gradual release of trenbolone from the ester; half‑life depends on the ester (hexahydrobenzylcarbonate is a relatively long‑acting ester; effects may persist for days to weeks).
- Detectable for a long time in blood/urine after use (important for doping tests).
3. Dosage — medical and varying usage guidelines
Important safety-first statement: there is no widely accepted, regulatory‑approved therapeutic dosing regimen for trenbolone in humans. The compound is not routinely prescribed for human clinical indications. The information below is descriptive only (reports in the medical and lay literature and user communities) and is not a recommendation or endorsement. Any consideration of use should involve full medical risk counseling and physician oversight.
Medical/approved use
- There are no standard, approved human therapeutic dosing recommendations for trenbolone hexahydrobenzylcarbonate in most countries. It is primarily a veterinary agent.
Reported (non‑medical / body‑building) dosing patterns (for informational/harm‑reduction purposes only)
- Frequency: Because the ester releases trenbolone over several days, injections are often reported from every 2–4 days up to daily micro‑dosing by some users.
- Dose ranges (reported anecdotally): • Low-to-moderate: ~25–50 mg every other day to 50 mg 2–3 times per week. • Moderate-high: ~75–150 mg every other day or approximately 200–400 mg per week. • Very high: >400 mg/week (markedly increases risk).
- Typical cycle lengths (reported): 6–12 weeks; longer exposure markedly increases risk of persistent endocrine and organ adverse effects.
Notes and cautions about dosing information
- These ranges are not safe or medically endorsed. Even “low” doses can cause serious adverse effects (endocrine suppression, cardiovascular changes, psychiatric effects, virilization in females).
- Women: the risk of virilization (voice deepening, clitoral enlargement, hirsutism, menstrual disruption) is high at relatively low doses. If ever considered in a medical context, female doses would be substantially lower and typically avoided; many experts advise against trenbolone in women for this reason.
- Special populations: contraindicated in children and adolescents (risk to growth and sexual maturation), in pregnancy and breastfeeding, and generally in patients with cardiovascular, hepatic, renal disease, or prostate/breast cancer risk.
- Injection technique, sterility, and product origin matter greatly — impurities, incorrect concentrations, or non-sterile technique can cause local and systemic infections and other harms.
Monitoring if exposure occurs or continues under medical supervision
- Baseline and periodic: blood pressure, fasting lipid panel, CBC (hematocrit/hemoglobin), liver function tests (AST/ALT; though 17α-alkylation‑type hepatotoxicity is not the main concern with trenbolone), renal function (creatinine, eGFR), fasting glucose or HbA1c, total testosterone, LH/FSH. In men >40 consider PSA.
- Cardiovascular risk assessment and close monitoring of mood/psychiatric symptoms.
Post-use (recovery) considerations
- HPG axis recovery after cessation can take weeks to months. In some cases hypogonadism can be prolonged and require endocrine evaluation. Medications that users employ for “post-cycle therapy” (SERMs, hCG) are not standard medical therapy for this compound and should only be used under endocrinology/urology guidance.
4. Side effects — common and rare adverse effects
Overview: trenbolone is associated with a high frequency of adverse effects affecting endocrine, cardiovascular, neuropsychiatric, dermatologic, and reproductive systems. Severity increases with dose and duration.
Common/adverse effects (frequently reported)
- Endocrine suppression: marked suppression of endogenous testosterone production; testicular atrophy and reduced sperm production.
- Androgenic/virilizing effects: acne, oily skin, accelerated male pattern baldness in those predisposed, voice deepening and clitoral enlargement in women.
- Cardiovascular/metabolic: increased LDL-cholesterol, decreased HDL-cholesterol, hypertension, increased hematocrit (polycythemia) — all increase cardiovascular risk.
- Psychiatric/behavioral: mood swings, irritability, aggression, anxiety, depression, insomnia. “Roid rage”‑type phenomena are reported but individual susceptibility varies.
- Injection-site reactions: pain, swelling, infection if aseptic technique is not used. “Tren cough”: an acute transient cough or shortness-of-breath-like reaction immediately after injection reported by many users — mechanism unclear but can be distressing.
- Sexual function: decreased libido or erectile dysfunction due to HPG axis suppression (despite exogenous androgens).
- Menstrual disturbances in women and amenorrhea.
Less common/serious/rare
- Gynecomastia: although trenbolone does not aromatize, its progestogenic activity can contribute to gynecomastia in some users.
- Thrombotic events: increased hematocrit and changes in lipids potentially increase risk of thrombosis, stroke, myocardial infarction — especially in people with preexisting risk factors.
- Renal effects: there are case reports suggesting renal strain or changes in renal function with AAS use; mechanisms not fully elucidated.
- Severe psychiatric events: severe depression, suicidality, psychosis in rare cases.
- Persistent hypogonadism: long-term or permanent suppression of the HPG axis after prolonged AAS use.
- Allergic or idiosyncratic reactions: rare hypersensitivity to constituents of the formulation.
Contraindications — absolute/relative
- Known prostate cancer or male breast cancer, pregnancy, breastfeeding, children and adolescents, severe cardiovascular disease, uncontrolled hypertension, severe hepatic or renal impairment, hypersensitivity to trenbolone or excipients.
Emergency signs that require immediate medical attention
- Chest pain, new or severe shortness of breath, sudden weakness/numbness, severe headache or vision changes (possible stroke), jaundice or dark urine (liver injury), markedly elevated blood pressure, signs of severe infection at injection site, new onset severe depression or suicidal ideation.
Drug interactions (clinical considerations)
- Concomitant use of other androgens/anabolic steroids increases adverse event risk (cardiometabolic, endocrine suppression).
- AAS may interact with anticoagulants (altered INR) — monitor carefully.
- Data on many drug–drug interactions for trenbolone specifically are limited.
5. Storage — how to store it
- Store at controlled room temperature unless the product label specifies otherwise (commonly 15–25 °C / 59–77 °F). Avoid freezing.
- Protect from light and moisture; keep the vial in its original container.
- Keep out of reach of children and pets.
- Do not use if the solution is cloudy (if labeled as a clear oil), contains particulate matter, or the seal is broken. Discard multi-dose vials after the labeled expiration date or if sterility has been compromised.
- For single-use vials, dispose of needles and syringes in a puncture‑resistant sharps container per local regulations. Do not reuse needles or syringes.
- If a product requires refrigeration per the manufacturer label (rare for conventional oil-based AAS), follow label instructions exactly.
Final summary and clinical advice
- Trenbolone (Parabolan) is a highly potent AAS with substantial potential for harm. It is not an approved general‑use therapeutic for most human indications. There are no evidence-based, safe dosing standards for humans.
- If exposure has occurred or is being considered, seek medical evaluation before starting or continuing. If someone is currently using the compound and has concerning symptoms (cardiovascular symptoms, jaundice, severe mood change, injection-site infection), they should seek immediate medical care.
- For monitoring, consider periodic cardiovascular, hematologic, endocrine and metabolic testing under physician supervision. An endocrinologist or addiction medicine specialist experienced with anabolic steroid complications is an appropriate consultant for management.
If you want, I can:
- summarize recommended laboratory monitoring schedules,
- list specific warning signs to watch for during/after a cycle,
- or provide a concise harm‑reduction checklist for clinicians advising a patient who discloses trenbolone use.
